| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 National Institute on Aging - NIH, Laboratory of Cardiovascular Science, Baltimore, MD, USA; Istituto Nazionale Ricovero e Cura per Anziani (INRCA), UO Geriatria, Roma, Italy
2 National Institute on Aging - NIH, Laboratory of Cardiovascular Science, Baltimore, MD, USA
3 National Institute on Aging - NIH, Clinical Research Branch, Baltimore, MD, USA
4 National Institute on Aging - NIH, Laboratory of Clinical Investigation, Baltimore, MD, USA
5 National Institute on Aging - NIH, Laboratory of Cardiovascular Science, Baltimore, MD, USA; Loyola College in Maryland, Baltimore, MD, USA
6 National Institute on Aging - NIH, Laboratory of Personality and Cognition, Baltimore, MD, USA
* To whom correspondence should be addressed. E-mail: SCUTERIA{at}GRC.NIA.NIH.GOV.
Background The aims of the present study were to compare the longitudinal changes in traditional CV risk factors (blood pressure, body mass index, total and HDL cholesterol, triglycerides, and blood glucose) in men with and without the ApoE4 allele. Subjects and Methods 306 men from the Baltimore Longitudinal Study of Aging, ranging in age from 20 to 92 years, were studied. Repeated measurements of CV risk factors were performed over a median follow-up time of 7 years (maximum 14.3 yrs) for men. Longitudinal changes in these CV risk factors were analysed via linear mixed-effects models. Results The prevalence of the ApoE4 allele was 25.5%. ApoE4 was independently associated with accelerated changes over time in fasting plasma glucose (+9.5% vs no change in those without ApoE4 in the sixth age-decade over 10 years). No significant effect of ApoE4 on longitudinal changes in total or HDL cholesterol, triglycerides or blood pressures was observed. Conclusion ApoE4 influences fasting plasma glucose and its changes over time. This could explain, in part, the increased CV risk associated with the ApoE4 genotype observed in men.
This article has been cited by other articles:
|
|
 |
|
  S. S. Najjar, A. Scuteri, V. Shetty, J. G. Wright, D. C. Muller, J. L. Fleg, H. P. Spurgeon, L. Ferrucci, and E. G. Lakatta Pulse Wave Velocity Is an Independent Predictor of the Longitudinal Increase in Systolic Blood Pressure and of Incident Hypertension in the Baltimore Longitudinal Study of Aging J. Am. Coll. Cardiol., April 8, 2008; 51(14): 1377 - 1383. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Bennet, E. Di Angelantonio, Z. Ye, F. Wensley, A. Dahlin, A. Ahlbom, B. Keavney, R. Collins, B. Wiman, U. de Faire, et al. Association of Apolipoprotein E Genotypes With Lipid Levels and Coronary Risk JAMA, September 19, 2007; 298(11): 1300 - 1311. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. DeKroon, J. B. Robinette, A. B. Hjelmeland, E. Wiggins, M. Blackwell, M. Mihovilovic, M. Fujii, J. York, J. Hart, C. Kontos, et al. APOE4-VLDL Inhibits the HDL-Activated Phosphatidylinositol 3-Kinase/Akt Pathway via the Phosphoinositol Phosphatase SHIP2 Circ. Res., October 13, 2006; 99(8): 829 - 836. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |
